Peng Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Hu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Xiaonan Sun
Department of Radiation Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, China
2 shared publications - Chao Chen
Radiology, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China
1 shared publication - Chongwei Wang
Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Chuanxi Lai
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
1 shared publication - Da Wang
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
1 shared publication - David W. Larson
Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3596
An Interpretable Multimodal Model Integrating Multiparametric MRI Radiomics and Body Composition for Preoperative Risk Stratification of Malignant Transformation in Rectal Adenomas: A Two-Center Study
Background/Objectives: Preoperative identification of malignant transformation in rectal adenomas (RAs) is challenging because endoscopic biopsy may not sample focal malignant components. This study aimed to develop and externally validate an interpretable multimodal model for preoperative risk stratification of malignant transformation in RAs. Methods: In this retrospective two-center study, 359 surgically treated patients were allocated to training (n = 143), internal validation (n = 61), and external validation (n = 155) cohorts. Radiomic features derived from high-resolution T2-weighted imaging (HRT2WI) and diffusion-weighted imaging (DWI), clinical biomarkers, and CT-derived body composition metrics were evaluated. Five machine learning algorithms were compared for each radiomics signature. The final combined logistic regression model integrated the selected HRT2WI and DWI radiomics model-predicted probabilities with clinical and body composition predictors. Discrimination, calibration, and decision curve analyses were performed. Results: The malignant transformation was present in 65/143 patients (45.5%) in the training cohort and 91/155 (58.7%) in the external cohort, a difference of 13.3 percentage points. The combined model achieved area under the receiver operating characteristic curve (AUC) values of 0.956 (95% CI, 0.922–0.981), 0.908 (95% CI, 0.830–0.970), and 0.867 (95% CI, 0.803–0.919) in the training, internal validation, and external validation cohorts, respectively. In external validation, the combined model outperformed the four component models and the junior radiologist (all p < 0.05); its performance did not differ significantly from that of the senior radiologist (p = 0.093). Note that this reader comparison included only one junior and one senior radiologist and is exploratory and cannot support general conclusions regarding model performance versus radiologists in broader clinical practice. SHapley Additive exPlanations (SHAP) analysis identified the visceral-to-subcutaneous fat ratio (VSR), DWI radiomics model-predicted probability, and the neutrophil-to-lymphocyte ratio (NLR) as the leading contributors to the combined model. Conclusions: This interpretable two-center model showed promising discrimination for preoperative risk stratification of malignant transformation in surgically treated RAs. It may help identify patients who warrant further preoperative assessment or multidisciplinary discussion. Prospective multicenter evaluation is required before clinical implementation.
- 23 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3596
Open AccessAn Interpretable Multimodal Model Integrating Multiparametric MRI Radiomics and Body Composition for Preoperative Risk Stratification of Malignant Transformation in Rectal Adenomas: A Two-Center Study
Background/Objectives: Preoperative identification of malignant transformation in rectal adenomas (RAs) is challenging because endoscopic biopsy may not sample focal malignant components. This study aimed to develop and externally validate an interpretable multimodal model for preoperative risk stratification of malignant transformation in RAs. Methods: In this retrospective two-center study, 359 surgically treated patients were allocated to training (n = 143), internal validation (n = 61), and external validation (n = 155) cohorts. Radiomic features derived from high-resolution T2-weighted imaging (HRT2WI) and diffusion-weighted imaging (DWI), clinical biomarkers, and CT-derived body composition metrics were evaluated. Five machine learning algorithms were compared for each radiomics signature. The final combined logistic regression model integrated the selected HRT2WI and DWI radiomics model-predicted probabilities with clinical and body composition predictors. Discrimination, calibration, and decision curve analyses were performed. Results: The malignant transformation was present in 65/143 patients (45.5%) in the training cohort and 91/155 (58.7%) in the external cohort, a difference of 13.3 percentage points. The combined model achieved area under the receiver operating characteristic curve (AUC) values of 0.956 (95% CI, 0.922–0.981), 0.908 (95% CI, 0.830–0.970), and 0.867 (95% CI, 0.803–0.919) in the training, internal validation, and external validation cohorts, respectively. In external validation, the combined model outperformed the four component models and the junior radiologist (all p < 0.05); its performance did not differ significantly from that of the senior radiologist (p = 0.093). Note that this reader comparison included only one junior and one senior radiologist and is exploratory and cannot support general conclusions regarding model performance versus radiologists in broader clinical practice. SHapley Additive exPlanations (SHAP) analysis identified the visceral-to-subcutaneous fat ratio (VSR), DWI radiomics model-predicted probability, and the neutrophil-to-lymphocyte ratio (NLR) as the leading contributors to the combined model. Conclusions: This interpretable two-center model showed promising discrimination for preoperative risk stratification of malignant transformation in surgically treated RAs. It may help identify patients who warrant further preoperative assessment or multidisciplinary discussion. Prospective multicenter evaluation is required before clinical implementation.
- 31 January 2025
- Published by Springer Nature in Pattern Analysis and Applications
- Vol. 28 (1) , 1-16
DE-NAF: decoupled neural attenuation fields for sparse-view CBCT reconstruction
- 31 January 2025
- Published by Springer Nature in Pattern Analysis and Applications
- Vol. 28 (1) , 1-16
DE-NAF: decoupled neural attenuation fields for sparse-view CBCT reconstruction
- Open Access
- 2 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 334-345
Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.
- 2 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 334-345
Open AccessEfficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.
- Open Access
- 18 January 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (1) , 535-546
Artemis as Predictive Biomarker of Responsiveness to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer
The aim of this study was to identify Artemis as a predictive biomarker for guiding preoperative chemoradiotherapy in locally advanced rectal cancer. The resection specimens were collected from 50 patients with rectal cancer who underwent preoperative chemoradiotherapy. Artemis expression in biopsy tissues was evaluated using immunohistochemical staining according to the percentage of positively stained cells combined with staining intensity. Among the 50 patients, 36 (72%) had a weakly positive Artemis protein expression, 10 (20%) had a moderately positive expression, and 4 (8%) showed a strongly positive expression. The criteria of magnetic resonance imaging tumor regression grade (mrTRG) and pathological rectal cancer regression grade (RCRG) were used to assess the tumor response to chemoradiotherapy. Correlation analysis shows that there is a significant negative correlation between high Artemis immunoscore and treatment response (r = −0.532, p < 0.001). The results imply that high Artemis expression was associated with poor treatment response. Our study suggested a potential role of Artemis as a predictive biomarker of the tumor response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
- 18 January 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (1) , 535-546
Open AccessArtemis as Predictive Biomarker of Responsiveness to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer
The aim of this study was to identify Artemis as a predictive biomarker for guiding preoperative chemoradiotherapy in locally advanced rectal cancer. The resection specimens were collected from 50 patients with rectal cancer who underwent preoperative chemoradiotherapy. Artemis expression in biopsy tissues was evaluated using immunohistochemical staining according to the percentage of positively stained cells combined with staining intensity. Among the 50 patients, 36 (72%) had a weakly positive Artemis protein expression, 10 (20%) had a moderately positive expression, and 4 (8%) showed a strongly positive expression. The criteria of magnetic resonance imaging tumor regression grade (mrTRG) and pathological rectal cancer regression grade (RCRG) were used to assess the tumor response to chemoradiotherapy. Correlation analysis shows that there is a significant negative correlation between high Artemis immunoscore and treatment response (r = −0.532, p < 0.001). The results imply that high Artemis expression was associated with poor treatment response. Our study suggested a potential role of Artemis as a predictive biomarker of the tumor response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
- 29 December 2022
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 39 (2) , 95-99
Preoperative Value of Contrast-Enhanced Ultrasound in Totally Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Liver Tumors: A Preliminary Study
The clinical data of 15 cases that planned to receive totally laparoscopic associating liver partition and portal vein ligation for staged hepatectomy were retrospectively collected. Before the stage 1 operation, the size and number of the tumors in future liver remnant (FLR) and the presence of cancer embolus in the portal vein were assessed using contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT). Before the stage 2 operation, CEUS was performed to assess the presence of traffic blood flow between the diseased liver and FLR after round-the-liver ligation. Before the stage 1 operation, 5 cases with tumors in FLR were found by CEUS and 6 cases were found by CECT (P > 0.05). Similarly, CEUS found 5 cases with cancer thrombus in portal vein, and CECT found 7 cases (P = 0.500). The consistency between the 2 modalities was good (κ = 0.857, P < 0.05, κ = 0.727, P < 0.05, respectively). Before the stage 2 operation, CEUS confirmed that there were 7 cases without traffic blood flow between the diseased liver and FLR, and 3 cases with residual traffic blood flow. The daily growth rate of FLR in the group without traffic blood flow (mean rank = 7.00) was higher than that in the group with traffic blood flow (2.00) significantly (P < 0.05). Contrast-enhanced ultrasound is a promising application in the preoperative evaluation of totally laparoscopic associating liver partition and portal vein ligation for staged hepatectomy.
- 29 December 2022
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 39 (2) , 95-99
Preoperative Value of Contrast-Enhanced Ultrasound in Totally Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Liver Tumors: A Preliminary Study
The clinical data of 15 cases that planned to receive totally laparoscopic associating liver partition and portal vein ligation for staged hepatectomy were retrospectively collected. Before the stage 1 operation, the size and number of the tumors in future liver remnant (FLR) and the presence of cancer embolus in the portal vein were assessed using contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT). Before the stage 2 operation, CEUS was performed to assess the presence of traffic blood flow between the diseased liver and FLR after round-the-liver ligation. Before the stage 1 operation, 5 cases with tumors in FLR were found by CEUS and 6 cases were found by CECT (P > 0.05). Similarly, CEUS found 5 cases with cancer thrombus in portal vein, and CECT found 7 cases (P = 0.500). The consistency between the 2 modalities was good (κ = 0.857, P < 0.05, κ = 0.727, P < 0.05, respectively). Before the stage 2 operation, CEUS confirmed that there were 7 cases without traffic blood flow between the diseased liver and FLR, and 3 cases with residual traffic blood flow. The daily growth rate of FLR in the group without traffic blood flow (mean rank = 7.00) was higher than that in the group with traffic blood flow (2.00) significantly (P < 0.05). Contrast-enhanced ultrasound is a promising application in the preoperative evaluation of totally laparoscopic associating liver partition and portal vein ligation for staged hepatectomy.